Terms: = Lung cancer AND PSA AND Treatment
197 results:
1. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
[TBL] [Abstract] [Full Text] [Related]
2. Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.
Lang Y; Lin Y; Deng M; Liu X
BMC Cancer; 2024 Feb; 24(1):236. PubMed ID: 38383374
[TBL] [Abstract] [Full Text] [Related]
3. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
Halabi S; Guo S; Park JJ; Nanus DM; George DJ; Antonarakis ES; Danila DC; Szmulewitz RZ; McDonnell DP; Norris JD; Lu C; Luo J; Armstrong AJ
Clin Cancer Res; 2024 Mar; 30(6):1152-1159. PubMed ID: 38236581
[TBL] [Abstract] [Full Text] [Related]
4. Lifetime Follow-Up of a Patient with Metastatic Prostate cancer Undergoing Multiple Surgical Resections: A Case Report.
Nanashima A; Nagayasu T; Yamasaki N; Tsuchiya T; Matsumoto K; Tagawa T; Arai J
Am J Case Rep; 2023 Nov; 24():e941668. PubMed ID: 37939016
[TBL] [Abstract] [Full Text] [Related]
5. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line treatment for Patients with Unresectable Advanced Non-small Cell lung cancer with PD-L1 Expression Status in Japan.
Chisaki Y; Nakano H; Minamide J; Yano Y
Clin Drug Investig; 2023 Nov; 43(11):839-850. PubMed ID: 37891362
[TBL] [Abstract] [Full Text] [Related]
6. Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate cancer Patients After Definitive treatment With psa Level ≤0.2 ng/mL.
Lu Y; Wilson ZJ; Xu G; Xu Z; Pan T; Wei P
Clin Nucl Med; 2023 Dec; 48(12):1021-1027. PubMed ID: 37801580
[TBL] [Abstract] [Full Text] [Related]
7. Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis.
Rui M; Wang Y; Li Y; Fei Z
BioDrugs; 2024 Jan; 38(1):157-170. PubMed ID: 37792142
[TBL] [Abstract] [Full Text] [Related]
8. Secondary Squamous Cell Carcinoma of Prostate: A Case Report.
Chen Q; Ye J; Li X; Chen R; Zeng S
Arch Esp Urol; 2023 Jun; 76(4):309-312. PubMed ID: 37455530
[TBL] [Abstract] [Full Text] [Related]
9. Synthesis and characterization of Hypsizygus ulmarius extract mediated silver nanoparticles (AgNPs) and test their potentiality on antimicrobial and anticancer effects.
Manimaran K; Yanto DHY; Anita SH; Nurhayat OD; Selvaraj K; Basavarajappa S; Hashem MI; Palanisamy G; Lin MC; Kumarasamy K
Environ Res; 2023 Oct; 235():116671. PubMed ID: 37454804
[TBL] [Abstract] [Full Text] [Related]
10. [HIFU therapy of localized prostate cancer using image-guided robotic HIFU Focal One].
Govorov AV; Vasilyev AO; Alaverdyan AI; Kolontarev KB; Pushkar DY
Urologiia; 2023 May; (2):83-89. PubMed ID: 37401710
[TBL] [Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
[TBL] [Abstract] [Full Text] [Related]
12. Prophylaxis for
Huang X; Huang X; Lin S; Luo S; Dong L; Lin D; Huang Y; Xie C; Nian D; Xu X; Weng X
BMJ Open; 2023 Mar; 13(3):e068943. PubMed ID: 36972963
[TBL] [Abstract] [Full Text] [Related]
13. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
[TBL] [Abstract] [Full Text] [Related]
14. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract] [Full Text] [Related]
15. Construction and validation of web-based nomograms for detecting and prognosticating in prostate adenocarcinoma with bone metastasis.
Dong Q; Wu X; Gan W; Mok TN; Shen J; Zha Z; Chen J
Sci Rep; 2022 Nov; 12(1):18623. PubMed ID: 36329203
[TBL] [Abstract] [Full Text] [Related]
16. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
Front Public Health; 2022; 10():956792. PubMed ID: 36016894
[TBL] [Abstract] [Full Text] [Related]
17. A Web-Based Prediction Model for cancer-Specific Survival of Elderly Patients Undergoing Surgery With Prostate cancer: A Population-Based Study.
Zhang Z; Zhanghuang C; Wang J; Mi T; Liu J; Tian X; Jin L; He D
Front Public Health; 2022; 10():935521. PubMed ID: 35903379
[TBL] [Abstract] [Full Text] [Related]
18. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China.
Rui M; Fei Z; Wang Y; Zhang X; Ma A; Sun H; Li H
J Med Econ; 2022; 25(1):618-629. PubMed ID: 35475459
[TBL] [Abstract] [Full Text] [Related]
19. Long term erectile function results of radical perineal prostatectomy.
Alper K; Ozgur Y; Akif E; Cubuk A; Murat T; Onder C; Oktay A; Selami A
Rev Int Androl; 2022; 20(3):152-157. PubMed ID: 35331662
[TBL] [Abstract] [Full Text] [Related]
20. Tumor-targeted delivery of honokiol via polysialic acid modified zein nanoparticles prevents breast cancer progression and metastasis.
Zhang Q; Li D; Guan S; Liu D; Wang J; Xing G; Yue L; Cai D
Int J Biol Macromol; 2022 Apr; 203():280-291. PubMed ID: 35093442
[TBL] [Abstract] [Full Text] [Related]
[Next]
